Aclarion, Inc. (NASDAQ:ACON) Short Interest Down 73.9% in March

Aclarion, Inc. (NASDAQ:ACON) was the recipient of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 122,800 shares, a drop of 73.9% from the February 28th total of 471,200 shares. Approximately 24.3% of the shares of the company are sold short. Based on an average daily trading volume, of 4,910,000 shares, the short-interest ratio is currently 0.0 days.

Wall Street Analyst Weigh In

ACON has been the topic of several analyst reports. Maxim Group reaffirmed a “hold” rating on shares of Aclarion in a report on Friday, December 13th. Ascendiant Capital Markets reduced their price target on Aclarion from $502.50 to $435.50 and set a “buy” rating for the company in a report on Wednesday, November 27th.

Aclarion Stock Down 23.0 %

NASDAQ:ACON opened at $0.58 on Thursday. The firm’s fifty day simple moving average is $2.90 and its 200-day simple moving average is $36.19. Aclarion has a fifty-two week low of $0.49 and a fifty-two week high of $231.15.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.